Fosfomycin: Mechanism and Resistance

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2017 Jan 8

PMID 28062557

Citations 126

Authors

Lynn L Silver

Affiliations

Soon will be listed here.

Abstract

Fosfomycin, a natural product antibiotic, has been in use for >20 years in Spain, Germany, France, Japan, Brazil, and South Africa for urinary tract infections (UTIs) and other indications and was registered in the United States for the oral treatment of uncomplicated UTIs because of Enterococcus faecalis and Escherichia coli in 1996. It has a broad spectrum, is bactericidal, has very low toxicity, and acts as a time-dependent inhibitor of the MurA enzyme, which catalyzes the first committed step of peptidoglycan synthesis. Whereas resistance to fosfomycin arises rapidly in vitro through loss of active transport mechanisms, resistance is rarely seen during therapy of UTIs, seemingly because of the low fitness of the resistant organisms. Recently, interest has grown in the use of fosfomycin against multidrug-resistant (MDR) pathogens in other indications, prompting the advent of development in the United States of a parenteral formulation for use, initially, in complicated UTIs. Whereas resistance has not been problematic in the uncomplicated UTI setting, it remains to be seen whether resistance remains at bay with expansion to other indications.

Citing Articles

Metabolic engineering approaches for the biosynthesis of antibiotics.

Yook G, Nam J, Jo Y, Yoon H, Yang D Microb Cell Fact. 2025; 24(1):35.

PMID: 39891166 PMC: 11786382. DOI: 10.1186/s12934-024-02628-2.

Identifying Opportunity Targets in Gram-Negative Pathogens for Infectious Disease Mitigation.

Paddy I, Dassama L ACS Cent Sci. 2025; 11(1):25-35.

PMID: 39866699 PMC: 11758222. DOI: 10.1021/acscentsci.4c01437.

From Isolation to Application: Utilising Phage-Antibiotic Synergy in Murine Bacteremia Model to Combat Multidrug-Resistant Enterococcus faecalis.

Yehia F, Yahya G, Elsayed E, Serrania J, Becker A, Gomaa S Microb Biotechnol. 2025; 18(1):e70075.

PMID: 39801028 PMC: 11725608. DOI: 10.1111/1751-7915.70075.

Novel Fosfomycin Resistance Mechanism in Due to Atypical Pho Regulon Control of GlpT.

Sanchez-Maroto L, Gella P, Couce A Antibiotics (Basel). 2024; 13(11).

PMID: 39596703 PMC: 11590989. DOI: 10.3390/antibiotics13111008.

Septal wall synthesis is sufficient to change ameba-like cells into uniform oval-shaped cells in Escherichia coli L-forms.

Hayashi M, Takaoka C, Higashi K, Kurokawa K, Margolin W, Oshima T Commun Biol. 2024; 7(1):1569.

PMID: 39587276 PMC: 11589767. DOI: 10.1038/s42003-024-07279-y.

References

De Smet K, Kempsell K, Gallagher A, Duncan K, Young D . Alteration of a single amino acid residue reverses fosfomycin resistance of recombinant MurA from Mycobacterium tuberculosis. Microbiology (Reading). 1999; 145 ( Pt 11):3177-3184. DOI: 10.1099/00221287-145-11-3177. View

Du W, Brown J, Sylvester D, Huang J, Chalker A, So C . Two active forms of UDP-N-acetylglucosamine enolpyruvyl transferase in gram-positive bacteria. J Bacteriol. 2000; 182(15):4146-52. PMC: 101887. DOI: 10.1128/JB.182.15.4146-4152.2000. View

Kahlmeter . The ECO*SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. J Antimicrob Chemother. 2000; 46 Suppl A:15-22. View

Kobayashi K, Ehrlich S, Albertini A, Amati G, Andersen K, Arnaud M . Essential Bacillus subtilis genes. Proc Natl Acad Sci U S A. 2003; 100(8):4678-83. PMC: 153615. DOI: 10.1073/pnas.0730515100. View

Nilsson A, Berg O, Aspevall O, Kahlmeter G, Andersson D . Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother. 2003; 47(9):2850-8. PMC: 182645. DOI: 10.1128/AAC.47.9.2850-2858.2003. View

Marchese A, Gualco L, Debbia E, Schito G, Schito A . In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents. 2003; 22 Suppl 2:53-9. DOI: 10.1016/s0924-8579(03)00230-9. View

Kock H, Gerth U, Hecker M . MurAA, catalysing the first committed step in peptidoglycan biosynthesis, is a target of Clp-dependent proteolysis in Bacillus subtilis. Mol Microbiol. 2004; 51(4):1087-102. DOI: 10.1046/j.1365-2958.2003.03875.x. View

Lemieux M, Huang Y, Wang D . Glycerol-3-phosphate transporter of Escherichia coli: structure, function and regulation. Res Microbiol. 2004; 155(8):623-9. DOI: 10.1016/j.resmic.2004.05.016. View

Eschenburg S, Priestman M, Schonbrunn E . Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release. J Biol Chem. 2004; 280(5):3757-63. DOI: 10.1074/jbc.M411325200. View

10.

GADEBUSCH H, Stapley E, Zimmerman S . The discovery of cell wall active antibacterial antibiotics. Crit Rev Biotechnol. 1992; 12(3):225-43. DOI: 10.3109/07388559209069193. View

11.

Kedar G, Brown-Driver V, Reyes D, Hilgers M, Stidham M, Shaw K . Comparison of the essential cellular functions of the two murA genes of Bacillus anthracis. Antimicrob Agents Chemother. 2008; 52(6):2009-13. PMC: 2415750. DOI: 10.1128/AAC.01594-07. View

12.

Falagas M, Giannopoulou K, Kokolakis G, Rafailidis P . Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008; 46(7):1069-77. DOI: 10.1086/527442. View

13.

Suarez J, Mendoza M . Plasmid-encoded fosfomycin resistance. Antimicrob Agents Chemother. 1991; 35(5):791-5. PMC: 245108. DOI: 10.1128/AAC.35.5.791. View

14.

Blake K, ONeill A, Mengin-Lecreulx D, Henderson P, Bostock J, Dunsmore C . The nature of Staphylococcus aureus MurA and MurZ and approaches for detection of peptidoglycan biosynthesis inhibitors. Mol Microbiol. 2009; 72(2):335-43. DOI: 10.1111/j.1365-2958.2009.06648.x. View

15.

Falagas M, Kastoris A, Karageorgopoulos D, Rafailidis P . Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents. 2009; 34(2):111-20. DOI: 10.1016/j.ijantimicag.2009.03.009. View

16.

Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, Martinez-Ruiz R . CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother. 2009; 64(4):712-7. DOI: 10.1093/jac/dkp288. View

17.

Castaneda-Garcia A, Rodriguez-Rojas A, Guelfo J, Blazquez J . The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa. J Bacteriol. 2009; 191(22):6968-74. PMC: 2772468. DOI: 10.1128/JB.00748-09. View

18.

Endimiani A, Patel G, Hujer K, Swaminathan M, Perez F, Rice L . In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother. 2009; 54(1):526-9. PMC: 2798518. DOI: 10.1128/AAC.01235-09. View

19.

Takahata S, Ida T, Hiraishi T, Sakakibara S, Maebashi K, Terada S . Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents. 2010; 35(4):333-7. DOI: 10.1016/j.ijantimicag.2009.11.011. View

20.

Falagas M, Kastoris A, Kapaskelis A, Karageorgopoulos D . Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010; 10(1):43-50. DOI: 10.1016/S1473-3099(09)70325-1. View